http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3487484-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7b6c089c2c8d445884aa559b243db1c0 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2009 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 |
| filingDate | 2017-07-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7469137255eff5b33687b0345d753978 |
| publicationDate | 2019-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-3487484-A1 |
| titleOfInvention | Atorvastatin composition |
| abstract | The invention relates to a solid pharmaceutical oral composition, comprising an atorvastatin salt in crystalline form as active ingredient, wherein the active substance has a particle size distribution with a D90 value of less than 100 µm. In order to further develop such a composition in such a way that the composition has a relatively high chemical stability with respect to the active ingredient, the composition, according to the invention, is directly pressed. |
| priorityDate | 2016-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 38.